Novavax (NASDAQ:NVAX) Earns News Sentiment Score of 0.03

News coverage about Novavax (NASDAQ:NVAX) has trended somewhat positive on Monday, Accern reports. Accern scores the sentiment of press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Novavax earned a news sentiment score of 0.03 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 45.8643824062263 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

These are some of the news headlines that may have impacted Accern Sentiment’s rankings:

NVAX has been the topic of several research reports. S&P Equity Research decreased their price target on shares of Novavax from $1.81 to $1.35 in a research note on Wednesday, January 10th. B. Riley set a $10.00 price target on shares of Novavax and gave the stock a “buy” rating in a research note on Thursday, January 11th. Ladenburg Thalmann Financial Services lifted their price target on shares of Novavax to $2.50 and gave the stock a “buy” rating in a research note on Thursday, January 11th. BidaskClub raised shares of Novavax from a “hold” rating to a “buy” rating in a research note on Saturday, December 30th. Finally, Citigroup raised shares of Novavax from a “neutral” rating to a “buy” rating and set a $2.00 price target on the stock in a research note on Tuesday, October 31st. Two research analysts have rated the stock with a sell rating, five have issued a hold rating and three have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $2.64.

Novavax (NASDAQ NVAX) opened at $2.34 on Monday. The company has a current ratio of 3.31, a quick ratio of 3.31 and a debt-to-equity ratio of -4.28. Novavax has a fifty-two week low of $0.73 and a fifty-two week high of $2.52.

COPYRIGHT VIOLATION WARNING: “Novavax (NASDAQ:NVAX) Earns News Sentiment Score of 0.03” was originally posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this article on another domain, it was illegally copied and republished in violation of United States and international copyright law. The legal version of this article can be accessed at https://ledgergazette.com/2018/02/19/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-novavax-nvax-stock-price.html.

Novavax Company Profile

Novavax, Inc is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases.

Insider Buying and Selling by Quarter for Novavax (NASDAQ:NVAX)

Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply